ArticleZdravstveno varstvo2026
Why Organised Cancer Screening Works: Lessons from Slovenia and the Next Phase of Evidence-Based Implementation.
Article in Zdravstveno varstvo, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Slovenia's experience shows that cancer screening becomes effective only when a test is embedded in an organised, population-based programme that reaches the target population equitably, assures quality across the whole pathway and uses individual- and programme-level data for improvement. Since the national roll-out of Programme ZORA for cervical cancer screening in 2003, followed by DORA for breast cancer screening in 2008 and Programme Svit for colorectal cancer screening in 2009, Slovenia has built a coherent screening infrastructure with visible population effects. Cervical and colorectal cancer incidence and mortality are decreasing, breast cancers detected through DORA are increasingly diagnosed at a localised stage, and Slovenia ranks among the strongest European performers in screening coverage and policy. This editorial argues that these achievements should be understood not as three isolated programme successes, but as the result of governance, registries, quality assurance, legal foundations, public trust and international alignment. The same principles must now guide the modernisation of existing programmes and the cautious, evidence-based introduction of lung, prostate and gastric cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.